+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07043400

Randomized Study Comparing Subcutaneous Versus Intravenous Tislelizumab Plus Chemotherapy for Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Led by BeOne Medicines · Updated on 2026-10-14

351

Participants Needed

95

Research Sites

25 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying adults with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that cannot be surgically removed or has spread to other parts of the body. This trial aims to compare the levels of drug exposure following treatment with tislelizumab given as a subcutaneous injection versus an intravenous infusion as first-line therapy. The study includes approximately 351 participants and is sponsored by BeOne Medicines. Participants are randomly assigned to one of two groups one group receives tislelizumab 300 mg as a subcutaneous injection on Day 1 of each 21-day cycle, followed by chemotherapy chosen individually the other group receives tislelizumab 200 mg as an intravenous infusion on Day 1 of each 21-day cycle, also followed by individualized chemotherapy. Chemotherapy drugs may include cisplatin, leucovorin, 5-fluorouracil, oxaliplatin, or capecitabine. The study is divided into a screening period, a treatment period, and a follow-up period. Throughout the study, participants will be monitored for drug levels, tumor response, survival, and adverse events for up to two years. Assessments include measuring the steady state trough concentration and area under the concentration-time curve of tislelizumab, as well as evaluating tumor response rates and disease control. Safety and antibody responses will also be tracked. Participants will undergo regular visits to collect medical data and ensure adherence to the treatment plan during the study period.

CONDITIONS

Brief Title

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Research Team

B

BeOne Medicines

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here